Biostar Pharmaceuticals Inc
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. It also provides OTC products, such as Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common … Read more
Biostar Pharmaceuticals Inc (BSPM) - Total Liabilities
Latest total liabilities as of September 2017: $5.28 Million USD
Based on the latest financial reports, Biostar Pharmaceuticals Inc (BSPM) has total liabilities worth $5.28 Million USD as of September 2017.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biostar Pharmaceuticals Inc - Total Liabilities Trend (2007–2016)
This chart illustrates how Biostar Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biostar Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Biostar Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HORN PETROLEUM
MU:H73
|
Germany | €8.70 Million |
|
iExalt Inc
OTCGREY:IEXA
|
USA | $4.71 Million |
|
AGILE PROP HOLD (A8P.SG)
STU:A8P
|
Germany | €190.90 Billion |
|
HTG Molecular Diagnostics Inc.
PINK:HTGMQ
|
USA | $10.39 Million |
|
Sabien Technology Group Plc
LSE:SNT
|
UK | GBX727.00K |
Liability Composition Analysis (2007–2016)
This chart breaks down Biostar Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biostar Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biostar Pharmaceuticals Inc (2007–2016)
The table below shows the annual total liabilities of Biostar Pharmaceuticals Inc from 2007 to 2016.
| Year | Total Liabilities | Change |
|---|---|---|
| 2016-12-31 | $5.62 Million | -20.78% |
| 2015-12-31 | $7.10 Million | -20.35% |
| 2014-12-31 | $8.91 Million | +85.99% |
| 2013-12-31 | $4.79 Million | -62.28% |
| 2012-12-31 | $12.70 Million | +90.72% |
| 2011-12-31 | $6.66 Million | -12.22% |
| 2010-12-31 | $7.59 Million | +24.57% |
| 2009-12-31 | $6.09 Million | +6.39% |
| 2008-12-31 | $5.72 Million | +44.73% |
| 2007-12-31 | $3.96 Million | -- |